Report Details Parkinson’s Diseases: World Drug Industry and Market 2016-2026 – our new study reveals trends, R&D progress, and predicted revenues Our new report discusses issues and events affecting the Parkinson’s disease therapeutics market. Our new report provides qualitative analyses to answer these key questions: - How is the Parkinson’s disease therapeutics market evolving? - What is driving and restraining the Parkinson’s disease therapeutics market? - How will political and regulatory factors influence the regional markets and submarkets? - Who are the leading Parkinson’s disease therapeutics companies, and what are their prospects over the forecast period? - What are the predictions for M&A activity, consolidation for existing players and the potential prospects for new market entrants?
Forecasts from 2016-2026 and other analyses show you commercial prospects Our new report provides quantitative analyses to answer these key questions: - What are the market shares of the Parkinson’s therapeutics disease market in 2015? - How will each of the drugs in the Parkinson’s therapeutics market grow over the forecast period and how much revenue will these drugs account for in 2026? - What Parkinson’s disease drugs are in the development pipeline? - How will each of Parkinson’s disease diagnostics market grow over the forecast period and how much revenue will these submarkets account for in 2026? - How will the market shares of the national markets change by 2026 and which geographical region will lead the market in 2026?
Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. We provide original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and STEP), company profiles and commercial developments. Read the full transcripts of two exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales.
Many opportunities exist for the treatment of Parkinson’s. Our new study shows you the most promising and lucrative parts of that CNS market, helping you stay ahead.
Discover sales predictions for the world market and submarkets Discover in our report overall world revenue to 2026 for Parkinson’s disease medicines. Also explore individual revenue predictions to 2026 for five therapeutic submarkets at world level: - Dopaminergic Agents - Dopamine Receptor Agonists - MAO-inhibitors - COMT-inhibitors - Other Therapeutic Options
Our investigation discusses what stimulates and restrains business. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.
See revenue forecasts for Parkinson’s disease drugs How will individual medicines perform from 2016 to 2026 at world level? Our study forecasts revenues of three brands sold by four companies: - Neupro (UCB) - Azilect (Teva) - Azilect (Lundbeck) - Comtan/Stalevo (Novartis)
What are the prospects in the leading regions and countries? Developments worldwide expand the market for diagnosing, treating and monitoring neurodegenerative disorders. Developed and developing national markets hold high potential from 2015.
Our work also shows individual revenue forecasts to 2026 for 11 national markets: - United States (US) - Japan - EU leaders – Germany, France, the UK, Italy and Spain (EU5) - BRIC nations – Brazil, Russia, India and China
Leading companies and potential for market growth In 2015 the overall world PD drug market generated $3217m. Visiongain predicts its revenues in 2020 to reach $3472m. Our work shows you what organisation hold greatest potential. See profiles of leading companies in this sector: - Novartis - Teva - UCB - Roche - Lundbeck
What affects producers of those medicines? Our report discusses issues and events affecting that industry and market from 2015, including these: - Research and development (R&D) – drugs, diagnostic tests, and related technologies - Disease prevalence – expanding patient populations - Disease-modifying drugs and obstacles to cures - Regulatory guidelines – changes and opportunities. - Drugs and related technologies to transform the market - Biomarkers - Deep brain stimulation (functional neuromodulation) - Intellectual property (IP), licensing agreements and partnerships.
Our 172-page report provides 120 charts. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and national level. You will see financial results, interviews trends and opportunities, and revenue predictions.
Benefit your work now through our updated study, gaining original industry and market analysis: - Revenues for Parkinson’s disease treatments to 2026 – assess that overall world drugs market’s potential and get forecasted revenues for the five leading sub-classes: dopaminergic agents, dopamine receptor agonists, COMT- and MAO-inhibitors and other therapeutic options. - Products’ sales to 2026 – discover predicted revenues Neupro, Comtan/Stalevo, and Azilect and see how those medicines can compete and succeed - National market forecasting to 2026 for 11 countries in the Americas, Europe and Asia – explore the best regions for treatment demand, sales and growth - R&D activities – see progress, trends and prospects in research and development, finding technological, clinical and commercial possibilities - Companies, news and opinions – examine participants, including Roche, Novartis, UCB and Lundbeck and get two exclusive interviews, helping your reputation for insight and staying ahead. Visiongain interviewed: - Dr. Russell Kern (Executive VP, Chief Scientific Officer): International Stem Cell Corporation, California, US - Professor Jian Feng PhD, Department of Physiology and Biophysics, University at Buffalo, the State University of New York. - Analysis of what stimulates and restrains that industry and market – assess challenges and strengths there, helping you compete and gain advantages.
Our reports have been used by over 10K customers, including:
Report Scope: This new report on the market for pharmaceutical treatments for mental health disorders provides a brief overview of the pharmaceutical markets, current and future treatments, as well as drug failure/withdrawals and barriers to entry. It examines changes in healthcare regulation and guidance in the development...
400 pages •
By The Business Research Company
• Feb 2021
Major companies in the residential substance abuse and mental health facilities market include National Health Service; Universal Health Services; Acadia Healthcare Company Inc; Kindred Healthcare Inc. and Genesis Healthcare. The global residential substance abuse and mental health facilities market is expected to grow from $73.73 billion...
Generation Z - Thematic Research
Generation Z is a demographic cohort born from 2000 to 2010. As the oldest of the generation reaches adulthood and seeks to enter the workforce, Gen Z consumers will exercise growing economic and cultural clout over the next decade.
Report Scope: This report provides an overview of the global market for exoskeletons and analyzes market trends.Using 2019 as the base year, the report provides estimated market data for the forecast period 2020 through 2025. Revenue forecasts for this period are segmented based on mobility, type, power, segment...
Narcolepsy - Pipeline Review, H2 2020
This latest Pharmaceutical and Healthcare disease pipeline guide Narcolepsy - Pipeline Review, H2 2020, provides an overview of the Narcolepsy (Central Nervous System) pipeline landscape.
Narcolepsy is a sleep disorder that causes excessive...
The current practice of medical education and methods of performing surgery and therapy suffer from limitations such as scarcity of subjects to practice on, suboptimal surgical precision, and therapy-related issues including medication misuse and ineffectiveness of the drugs to treat the conditions. Moreover, the outbreak of COVID-19 pandemic...
Metabotropic Glutamate Receptor 2 - Pipeline Review, H2 2020
According to the recently published report ’Metabotropic Glutamate Receptor 2 - Pipeline Review, H2 2020’; Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) pipeline Target constitutes close to 12 molecules. Out of...
116 pages •
By Asia Market Information & Development Company
• Sep 2020
This study focuses on China’s Central Nervous System Disorder Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.